83
Views
0
CrossRef citations to date
0
Altmetric
Patent Evaluations

Use of a peptide enhancing the ability of radiation therapy to kill cancer cells: a patent evaluation of WO2012016918

, MD & , MD PhD
Pages 1485-1487 | Published online: 08 Aug 2012
 

Abstract

Background: Faulty apoptosis is a known mechanism that leads to resistance to radiotherapy. The application (WO2012016918A1) deals with a peptide useful for disrupting this resistance mechanism and enhancing the efficiency of radiotherapy.

Methods: A peptide consisting essentially of the N2 sequence of the RasGAP protein is conjugated to the HIV-TAT48–57 cell permeation sequence. The DNA sequence encoding the peptide (TAT-RasGAP317–326) is synthesized and introduced into the host cells.

Results: TAT-RasGAP317–326 is demonstrated to potentiate the efficacy of γ-irradiation-mediated cell killing both in tumor cell lines and in mouse tumor models, disregarding the status of p53, but not in non-cancer cells.

Conclusion: TAT-RasGAP317–326 peptide favors apoptosis of tumor cells, but not normal cells in response to radiotherapy. The invention provides a specific method that is probably to be used in cancers that are radio-resistant.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,757.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.